EE115 Cost-Effectiveness and Cost-Utility Analyses of Polatuzumab Vedotin With Rituximab and Chemotherapy vs Rituximab and Chemotherapy in Treating Naïve Diffuse Large B-Cell Lymphoma in Italy
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.367
https://www.valueinhealthjournal.com/article/S1098-3015(22)02571-2/fulltext
Title :
EE115 Cost-Effectiveness and Cost-Utility Analyses of Polatuzumab Vedotin With Rituximab and Chemotherapy vs Rituximab and Chemotherapy in Treating Naïve Diffuse Large B-Cell Lymphoma in Italy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02571-2&doi=10.1016/j.jval.2022.09.367
First page :
Section Title :
Open access? :
No
Section Order :
12173